{"paper_id":"9cf65bc8-afd0-4831-bea0-6286f028d8c1","body_text":"References\nBarbieri RL (1988) New therapy for endometriosis. N Engl J Med 318:512–514\nMaouris P (1989) A new treatment for Endometriosis. The Lancet 1:1017–1018\nMatta WH, Shaw RW, Hesp R, Katz D (1987) Hypogonadism induced by hormone relesing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J 294:1523\nMeldrum DR, Chan RJ, Lu J, Vale W, Rivier J, Judd HL (1982) “Medical oophorectomy” using a long-acting GnRH agonist — a possible new approch to the treatment of endometriosis. J Clin Endocrinol Metab 54:1081\nDiZerega GS, Barber DL, Hodgen GD (1980) Enometriosis: role of ovarian steroids in initiation, maintence and suppresion. Fertil Steril 33:649–653\nRoddick JW, Conkey G, Jacobs EJ (1960) The hormonal response of enodometrotic implants and its relationship to symptomatology. Am J Obstet Gynecol 79:1173\nAuthor information\nAuthors and Affiliations\nRights and permissions\nAbout this article\nCite this article\nRosen, A., Klein, M. & Beck, A. Transdermal oestrogene application a contraindication in therapy of endometriosis with Gonadotropin-Releasing Hormon analogues. Klin Wochenschr 68, 537 (1990). https://doi.org/10.1007/BF01648254\nReceived:\nAccepted:\nIssue date:\nDOI: https://doi.org/10.1007/BF01648254","source_license":"CC0","license_restricted":false}